Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review

Cephalalgia

Volumn 33, Issue 13, 2013, Pages 1122-1131

  Tfelt Hansen, Peer C ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dihydroergotamine; long duration; migraine; slow action

Indexed keywords

DIHYDROERGOTAMINE; PLACEBO; PROCHLORPERAZINE; SUMATRIPTAN;

ANALGESIA; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THERAPY EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

DIHYDROERGOTAMINE; LONG DURATION; MIGRAINE; SLOW ACTION;

ANALGESICS, NON-NARCOTIC; DIHYDROERGOTAMINE; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME;

EID: 84884174506     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413483372     Document Type: Review

References (42)

1. Dahlöf C, Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012 ; 52: 707-714
2. Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol. 2010 ; 161: 488-508
3. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetic and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther. 1979 ; 25: 358-371
4. Holford NHG, Sheiner LB. Kinetics of pharmacological response. Pharmacol Ther. 1982 ; 16: 143-166
5. Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: Plasma levels and dynamic activity. Clin Pharmacol Ther. 1985 ; 37: 29-35
6. Tfelt-Hansen P. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol. 1986 ; 59: 1-30
7. Atkinson AJ, Lalonde RL. Introduction of quantitative methods in pharmacology and clinical pharmacology: A historical overview. Clin Pharmacol Ther. 2007 ; 82: 3-6
8. Aellig WH, Rosenthaler J. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol. 1986 ; 30: 581-584
9. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996 ; 53: 180-184
10. Saper JR, Silberstein S, Dodick D, et al. DHE in the pharmacotherapy of migraine: Potential for a larger role. Headache. 2006 ; 46: S212 - S220
11. Tfelt-Hansen P, Saxena PR The headaches. 2 nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000, pp. 399-409. Olesen J Tfelt-Hansen P Welch KMA, ed. Philadelphia: Lippincott Williams & Wilkins ; 2000: 399-409.
12. Tfelt-Hansen P, Saxena PR The headaches. 3 rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006, pp. 459-467. Olesen J Goadsby PJ Ramadan NM, ed. Philadelphia: Lippincott Williams & Wilkins ; 2006: 459-467.
13. Aurora SK, Rozen TD, Kori SH, et al. A randomized, double-blind, placebo-controlled study of MAP0004 in adult patient with migraine. Headache. 2009 ; 49: 826-837
14. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004. Orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache. 2011 ; 51: 507-517
15. Silberstein S. MAP0004: Dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012 ; 13: 1961-1968
16. Rapoport AM. Acute treatment of migraine: Established and emerging therapies. Headache. 2012 ; 52: S60 - S64
17. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010 ; 9: 285-298
18. Kori S, Kellerman DJ, Voloshko P, et al. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: A randomized, double-blind, active- and placebo-controlled study in healthy volunteers. Clin Ther. 2012 ; 34: 1920-1928
19. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996 ; 119: 249-256
20. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986 ; 26: 168-171
21. González-Espinosa LE, Gómez-Viera N, Olivera-Leal I, et al. Treatment of acute attacks of migraine with sumatriptan [in Spanish]. Rev Neurol. 1997 ; 25: 1672-1675
22. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache. 1995 ; 35: 177-184
23. Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol. 1996 ; 53: 1285-1291
24. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994 ; 44: 447-453
25. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995 ; 26: 541-546
26. Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med. 1996 ; 14: 262-264
27. de Hoon JN, Poppe KA, Thijssen HH, et al. Dihydroergotamine: Discrepancy between arterial, arteriolar and pharmacokinetic data. Br J Clin Pharmacol. 2001 ; 52: 45-51
28. Scott AK. Dihydroergotamine: A review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol. 1992 ; 15: 289-296
29. Humbert H, Cabiac M-D, Dubray C, et al. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther. 1996 ; 60: 265-275
30. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology. 1996 ; 47: 361-365
31. Tfelt-Hansen P. A comment on time-to-event analysis for headache relief. Cephalalgia. 2000 ; 20: 255-256
32. Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract. 2000 ; 54: 281-286
33. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler. Headache. 2008 ; 48: 355-367
34. Müller-Schweinitzer E. In vitro studies on the duration of action of dihydroergotamine. In J Clin Pharmacol Ther Toxicol. 1980 ; 18: 88-91
35. Tfelt-Hansen P, Nilsson E, Edvinsson L. Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat. J Headache Pain. 2007 ; 8: 83-89
36. Maassen Van Den Brink A, Reekers M, Bax W, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998 ; 98: 25-30
37. Kori S, Zhang J, Kellerman D, et al. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. (abstract) Conference Programme. London, September 2012, European Headache and Migraine Trust International Congress, p.102.
38. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 ; 46: S171 - S181
39. Lindblad B, Abisch E, Bergquist D. The pharmacokinetics of subcutaneous dihydroergotamine with and without dextran 70 infusion. Eur J Clin Pharmacol. 1983 ; 24: 813-818
40. Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol. 1984 ; 26: 473-470
41. Tfelt-Hansen P, Hougaard A. Sumatriptan: A review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. Expert Opin Drug Metab Toxicol. 2013 ; 9: 91-103
42. Saxena PR, Tfelt-Hansen P The headaches. 5 HT1B/1D agonists in the acute treatment of migraine. In: OlesenJGoadsbyPJRamadanNM (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006, pp. 469-503. Olesen J Goadsby PJ Ramadan NM, ed. Philadelphia: Lippincott Williams & Wilkins ; 2006: 469-503.